United States Import Data for Blood and Vaccines Under HS Code 3002
HS Code 3002 is officially defined as Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) and similar products in United States. United States classifies these goods under the Harmonized Tariff Schedule of the United States (HTS / HTSUS), which extends the 6-digit HS to 10 digits. Explore United States import shipment records for Blood and Vaccines classified under HS Code 3002.
Latest United States Import Trade Records For Blood and Vaccines Under HS Code 3002
As of 2026-09-28, companies recorded in United States import shipments of Blood and Vaccines (HS Code 3002) include Pt Prodia Widyahusada, товарищество с ограниченной ответственностью Vortex Kz /вортекс кз/ and Biological E. Limited, as declared on bill of lading trade records. These shipments originate from INDONESIA, KAZAKHSTAN and INDIA. In 2025, United States's total import value for Blood and Vaccines was US$ 110,630,663,133. Full shipment records include fields such as exporter, importer, country of origin, destination country, trade value, weight, quantity, and ports of loading and discharge.
Subscribe Now to run unlimited searches and unlock full shipment records, trade partners and trade metrics for Blood and Vaccines under HS Code 3002.
1-10 of 8,200M+ Bill of Lading database covers import export Trade records updated till 2026-09-28
Access Full & Detailed Trade Data for HS Code 3002
Reveal full shipment records, buyers, suppliers and trade metrics for Blood and Vaccines, and run unlimited searches across TradeInt global trade database.
Top Import Products Under HS Code 3002 (Blood and Vaccines) in United States
Based on United States import trade data, top import products under HS Code 3002 in United States are:
Aggregated United States import data for 2025.